ReviewFrontiers in medicine2017
Progressive Hemifacial Atrophy and Linear Scleroderma En Coup de Sabre: A Spectrum of the Same Disease?
Review in Frontiers in medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- CT imaging-led diagnosis of Parry-Romberg syndrome: A case report and literature review highlighting craniofacial and neurologic involvement.Radiology case reports · 2026Article
- Intrauterine stroke from a sword on the face - A rare diagnosis and its long-term sequelae.Indian journal of ophthalmology · 2026Article
- Article
- Autologous adipose tissue transfer in progressive hemifacial atrophy: From simple volume to regenerative cell therapy.JPRAS open · 2025Review
- Article
- Article
- Magnetic Resonance Imaging in the Assessment and Management of Post-injection-Site Morphea.Cureus · 2024Article
- Clinical and therapeutic course in head variants of linear morphea in adults: a retrospective review.Archives of dermatological research · 2023Article
- Occlusive retinal vasculitis associated with systemic sclerosis and antiphospholipid antibodies.American journal of ophthalmology case reports · 2021Article
- Therapeutic and Reconstructive Management Options in Scleroderma (Morphea) en Coup de Sabre in Children and Adults. A Systematic Literature Review.Journal of clinical medicine · 2021Review
- Parry Romberg disease with En Coup de Sabre Scleroderma: Effect of tocilizumab on periodontal bone inflammation.Journal of scleroderma and related disorders · 2021Article
- Secukinumab treatment of Parry-Romberg syndrome.JAAD case reports · 2020Article
- Linear Scleroderma of the Head - Updates in management of Parry Romberg Syndrome and En coup de sabre: A rapid scoping review across subspecialties.European journal of rheumatology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Similar clinical and histhopathological features in progressive hemifacial atrophy and linear scleroderma en coup de sabre are well known. Trauma may predispose to the development of both diseases. The lack of association with anti-Borrelia antibodies was shown in both cases as well. The otolaryngological and endocrine disorders may be associated findings in both diseases. However, there are certain differences in neurological and ophthalmological changes in the diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.